Učitavanje...
PARP1 suppresses homologous recombination events in mice in vivo
Recent studies suggest that PARP1 inhibitors, several of which are currently in clinical trial, may selectively kill BRCA1/2 mutant cancers cells. It is thought that the success of this therapy is based on immitigable lethal DNA damage in the cancer cells resultant from the concurrent loss or inhibi...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2995050/ https://ncbi.nlm.nih.gov/pubmed/20660013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gkq624 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|